The authors compared how often harms were reported with gemcitabine against all other drugs in 18.37 million FDA reports from 2014 to 2026. Myelosuppression was reported 3.35 to 7.74 times more often than expected, whether gemcitabine was given alone or in combination. A liver toxicity signal of 10.32 for three-drug regimens fell to 1.62 when only reports naming gemcitabine as the suspected cause were counted.
Why it is interesting: How far a reporting signal moves once the counting rule changes, for a first-line cancer regimen.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.